Cognition Therapeutics

OverviewSuggest Edit

Cognition Therapeutics operates as a biopharmaceutical company. The company discovers and develops small molecule therapeutics targeting toxic proteins that cause cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain.
TypePrivate
Founded2007
HQPittsburgh, US
Websitecogrx.com

Latest Updates

Employees (est.) (Nov 2019)23(-4%)

Key People/Management at Cognition Therapeutics

Robert Gailus

Robert Gailus

Chairman of the Board
Mark H. Breedlove

Mark H. Breedlove

General Partner, Breedlove Family LP
Susan Catalano

Susan Catalano

Co-Founder and Chief Science Officer
Aaron Fletcher

Aaron Fletcher

Founder and President, Bios Research
Kenneth I. Moch

Kenneth I. Moch

President and Chief Executive Officer
Irwin Scher

Irwin Scher

Chairman and Founder
Show more

Cognition Therapeutics Office Locations

Cognition Therapeutics has an office in Pittsburgh
Pittsburgh, US (HQ)
2403 Sidney St.
Show all (1)

Cognition Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2007

Cognition Therapeutics total Funding

$81.7 m

Cognition Therapeutics latest funding size

$3.30 m

Time since last funding

4 months ago

Cognition Therapeutics investors

Cognition Therapeutics's latest funding round in July 2019 was reported to be $3.3 m. In total, Cognition Therapeutics has raised $81.7 m
Show all financial metrics

Cognition Therapeutics Online and Social Media Presence

Embed Graph

Cognition Therapeutics Blogs

Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer

PITTSBURGH, November 4, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that James M. O’Brien has joined the Company as chief financ…

Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting

PITTSBURGH, October 15, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Fourth International Symposium on Sig…

Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting

PITTSBURGH, October 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the Company would be presenting three posters on Elayta…

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference

PITTSBURGH, September 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the company’s co-founder and chief science officer, S…

Cognition Therapeutics to Give Webcast Presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019

PITTSBURGH, September 04, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that President & CEO Kenneth I. Moch will be presentin…

National Institute on Aging

The NIA Small Business Award Program aims to support the discovery, development and commercialization of new therapies, novel devices, analytical tools, health care programs and practices that will improve prevention and treatment, as well as caregiving for patients with Alzheimer’s disease and rela…
Show more

Cognition Therapeutics Frequently Asked Questions

  • When was Cognition Therapeutics founded?

    Cognition Therapeutics was founded in 2007.

  • Who are Cognition Therapeutics key executives?

    Cognition Therapeutics's key executives are Robert Gailus, Mark H. Breedlove and Susan Catalano.

  • How many employees does Cognition Therapeutics have?

    Cognition Therapeutics has 23 employees.

  • Who are Cognition Therapeutics competitors?

    Competitors of Cognition Therapeutics include Kither Biotech, CANbridge Life Sciences and Fortress Biotech.

  • Where is Cognition Therapeutics headquarters?

    Cognition Therapeutics headquarters is located at 2403 Sidney St., Pittsburgh.

  • Where are Cognition Therapeutics offices?

    Cognition Therapeutics has an office in Pittsburgh.

  • How many offices does Cognition Therapeutics have?

    Cognition Therapeutics has 1 office.